Sensei Biotherapeutics, Inc. (SNSE) Stock Score, Valuation & Financial Research

Sensei Biotherapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SNSE

Sensei Biotherapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 13.85. These figures are a research snapshot, not a buy or sell recommendation.

What Sensei Biotherapeutics, Inc. does

Sensei Biotherapeutics, Inc. (SNSE) is a biopharmaceutical firm dedicated to discovering and advancing immunotherapies, primarily for cancer treatment. The company's innovative approaches include its proprietary ImmunoPhage platform. This immunotherapy leverages bacteriophages to orchestrate a precise and robust innate and adaptive immune response. They also employ the Tumor Microenvironment Activated Biologics (TMAB) platform. This system is engineered to unleash T-cells' anti-tumor capabilities, utilizing human monoclonal antibodies specifically designed to operate within the tumor's immediate environment and target key immune checkpoints or other crucial signaling pathways. Sensei Biotherapeutics' pipeline features SNS-101, a monoclonal antibody developed for cancer therapy, and SNS-401-NG, an ImmunoPhage vaccine engineered to target a range of tumor antigens. Furthermore, they collaborate with The University of Washington on the research and development of a vaccine for Merkel cell carcinoma. Established in 1999, originally as Panacea Pharmaceuticals, Inc., Sensei Biotherapeutics maintains its headquarters in Rockville, Maryland.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation cancer immunotherapies. The company operates as a research and development entity that has not yet generated commercial revenue from product sales, relying instead on capital raises and potential future licensing or collaboration agreements to fund its pipeline of antibody-based therapeutics.

Products and services

  • The company's primary product candidate is SNS-101, a conditionally active monoclonal antibody designed to target the V-domain Ig suppressor of T cell activation (VISTA) pathway for the treatment of solid tumors.

Customer types

Clinical trial participants.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials and drug candidates. Source

Competitors and product-market comparisons

  • Large pharmaceutical and biotechnology companies — Companies developing immuno-oncology therapies, including those targeting PD-1, PD-L1, and other immune checkpoints. Source

Business strengths to evaluate

  • Proprietary Immuno-Oncology Platform Source

Business risks and research considerations

  • History of operating losses and lack of commercial revenue Source
  • Dependence on third-party manufacturers Source
  • Clinical trial failure or delays Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SNSE financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 13.85
Market capitalization:
18.59M (currency not supplied)
Revenue:
USD -4.85M
Net income:
USD -195.53M
Free cash flow:
USD -20.47M
Cash:
USD 26.9M
Total debt:
USD 592K
EPS:
USD -146.83

What stands out

  • Free cash flow is USD -20.47M, negative for the stored period.
  • The balance sheet shows USD 26.9M of cash versus USD 592K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 26.31M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SNSE

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can SNSE fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is SNSE likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for SNSE to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of SNSE's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research SNSE

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.